FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204826579> ?p ?o ?g. }

• W3204826579 endingPage "1375" @default.
• W3204826579 startingPage "1367" @default.
• W3204826579 abstract "BACKGROUND: Pancreatic cancer is associated with low median overall survival. Combination chemotherapy regimens FOLFIRINOX and gemcitabine with nab-paclitaxel (GemNab) are the new adjuvant treatment standards for resectable pancreatic cancer. PRODIGE-24 and APACT trials demonstrated superior clinical outcomes with FOLFIRINOX and GemNab, each vs gemcitabine monotherapy. OBJECTIVE: To evaluate the cost-effectiveness of FOLFIRINOX vs GemNab for resectable pancreatic cancer in adults from the U.S. payer perspective, in order to inform decision makers about which of these treatments is optimal. METHODS: A Markov model with 3 disease states (relapse free, progressive disease, and death) was developed. Cycle length was 1 month, and time horizon was 10 years. Transition probabilities were derived from PRODIGE-24 and APACT survival data. All cost and utility input parameters were obtained from published literature. Cost-effectiveness analysis was performed to obtain total costs, quality-adjusted life-years (QALYs), life-years (LYs), and incremental cost-effectiveness ratio (ICER). A 3% annual discount rate was applied to costs and outcomes. The effect of uncertainty on model parameters was assessed with 1-way and probabilistic sensitivity analysis (PSA). RESULTS: Our analysis estimated that the cost for FOLFIRINOX was $40,831 higher than GemNab ($99,669 vs. $58,837). Despite increased toxicity, FOLFIRINOX was associated with additional 0.18 QALYs and 0.25 LYs compared with GemNab (QALY: 1.65 vs. 1.47; LY: 2.09 vs. 1.84). The ICER for FOLFIRINOX vs GemNab was $226,841 per QALY and $163,325 per LY. FOLFIRINOX was not cost-effective at a willingness-to-pay (WTP) threshold of $200,000 per QALY, and this was confirmed by the PSA. CONCLUSIONS: Total monthly cost for FOLFIRINOX was approximately 1.7 times higher than GemNab. If the WTP threshold increases to or above $250,000 per QALY, FOLFIRINOX then becomes a cost-effective treatment option. DISCLOSURES: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to declare." @default.
• W3204826579 created "2021-10-11" @default.
• W3204826579 creator A5010122390 @default.
• W3204826579 creator A5048276466 @default.
• W3204826579 creator A5056739096 @default.
• W3204826579 creator A5058217274 @default.
• W3204826579 date "2021-10-01" @default.
• W3204826579 modified "2023-10-16" @default.
• W3204826579 title "Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials" @default.
• W3204826579 cites W1550258061 @default.
• W3204826579 cites W166560170 @default.
• W3204826579 cites W1834918759 @default.
• W3204826579 cites W2005295931 @default.
• W3204826579 cites W2011000634 @default.
• W3204826579 cites W2055760927 @default.
• W3204826579 cites W2088735383 @default.
• W3204826579 cites W2089030557 @default.
• W3204826579 cites W2127554019 @default.
• W3204826579 cites W2168781879 @default.
• W3204826579 cites W2328000985 @default.
• W3204826579 cites W2540592748 @default.
• W3204826579 cites W2559912395 @default.
• W3204826579 cites W2581973599 @default.
• W3204826579 cites W2595351273 @default.
• W3204826579 cites W2618311913 @default.
• W3204826579 cites W2792261741 @default.
• W3204826579 cites W2805464686 @default.
• W3204826579 cites W2893799469 @default.
• W3204826579 cites W2903623792 @default.
• W3204826579 cites W2917919815 @default.
• W3204826579 cites W2959224028 @default.
• W3204826579 cites W2980244248 @default.
• W3204826579 cites W3007914843 @default.
• W3204826579 cites W3024200867 @default.
• W3204826579 cites W3033718997 @default.
• W3204826579 cites W3041116763 @default.
• W3204826579 cites W4249475443 @default.
• W3204826579 doi "https://doi.org/10.18553/jmcp.2021.27.10.1367" @default.
• W3204826579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34595948" @default.
• W3204826579 hasPublicationYear "2021" @default.
• W3204826579 type Work @default.
• W3204826579 sameAs 3204826579 @default.
• W3204826579 citedByCount "2" @default.
• W3204826579 countsByYear W32048265792022 @default.
• W3204826579 crossrefType "journal-article" @default.
• W3204826579 hasAuthorship W3204826579A5010122390 @default.
• W3204826579 hasAuthorship W3204826579A5048276466 @default.
• W3204826579 hasAuthorship W3204826579A5056739096 @default.
• W3204826579 hasAuthorship W3204826579A5058217274 @default.
• W3204826579 hasBestOaLocation W32048265791 @default.
• W3204826579 hasConcept C112930515 @default.
• W3204826579 hasConcept C121608353 @default.
• W3204826579 hasConcept C126322002 @default.
• W3204826579 hasConcept C143998085 @default.
• W3204826579 hasConcept C2777148230 @default.
• W3204826579 hasConcept C2780210213 @default.
• W3204826579 hasConcept C2780258809 @default.
• W3204826579 hasConcept C2780259306 @default.
• W3204826579 hasConcept C3019080777 @default.
• W3204826579 hasConcept C526805850 @default.
• W3204826579 hasConcept C71924100 @default.
• W3204826579 hasConceptScore W3204826579C112930515 @default.
• W3204826579 hasConceptScore W3204826579C121608353 @default.
• W3204826579 hasConceptScore W3204826579C126322002 @default.
• W3204826579 hasConceptScore W3204826579C143998085 @default.
• W3204826579 hasConceptScore W3204826579C2777148230 @default.
• W3204826579 hasConceptScore W3204826579C2780210213 @default.
• W3204826579 hasConceptScore W3204826579C2780258809 @default.
• W3204826579 hasConceptScore W3204826579C2780259306 @default.
• W3204826579 hasConceptScore W3204826579C3019080777 @default.
• W3204826579 hasConceptScore W3204826579C526805850 @default.
• W3204826579 hasConceptScore W3204826579C71924100 @default.
• W3204826579 hasIssue "10" @default.
• W3204826579 hasLocation W32048265791 @default.
• W3204826579 hasLocation W32048265792 @default.
• W3204826579 hasOpenAccess W3204826579 @default.
• W3204826579 hasPrimaryLocation W32048265791 @default.
• W3204826579 hasRelatedWork W1975191131 @default.
• W3204826579 hasRelatedWork W2559093989 @default.
• W3204826579 hasRelatedWork W2599910524 @default.
• W3204826579 hasRelatedWork W2736952847 @default.
• W3204826579 hasRelatedWork W284685154 @default.
• W3204826579 hasRelatedWork W3045328550 @default.
• W3204826579 hasRelatedWork W3154040450 @default.
• W3204826579 hasRelatedWork W3173108227 @default.
• W3204826579 hasRelatedWork W3177534832 @default.
• W3204826579 hasRelatedWork W4307429747 @default.
• W3204826579 hasVolume "27" @default.
• W3204826579 isParatext "false" @default.
• W3204826579 isRetracted "false" @default.
• W3204826579 magId "3204826579" @default.
• W3204826579 workType "article" @default.